The relationship between hyperhomocysteinemia and neurodegeneration

Papers of special note have been highlighted as: • of interest

References

• 1 Mandaviya PR, Stolk L, Heil SG. Homocysteine and DNA methylation: a review of animal and human literature. Mol. Genet. Metab. 113(4), 243–252 (2014).
  Medline CASGoogle Scholar
• 2 Vacek TP, Kalani A, Voor MJ, Tyagi SC, Tyagi N. The role of homocysteine in bone remodeling. Clin. Chem. Lab. Med. 51(3), 579–590 (2013).
  Medline CASGoogle Scholar
• 3 Petramala L, Acca M, Francucci CM, D'Erasmo E. Hyperhomocysteinemia: a biochemical link between bone and cardiovascular system diseases? J. Endocrinol. Invest. 32(Suppl. 4), 10–14 (2009).
  Medline CASGoogle Scholar
• 4 Ansari R, Mahta A, Mallack E, Luo JJ. Hyperhomocysteinemia and neurologic disorders: a review. J. Clin. Neurol. 10(4), 281–288 (2014).
  MedlineGoogle Scholar
• 5 Zhuo JM, Wang H, Praticò D. Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol. Sci. 32(9), 562–571 (2011).
  Medline CASGoogle Scholar
• 6 Nachum-Biala Y, Troen AM. B-vitamins for neuroprotection: narrowing the evidence gap. Biofactors 38(2), 145–150 (2012).
  Medline CASGoogle Scholar
• 7 Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst. Rev. (4), CD004514 (2003).
  MedlineGoogle Scholar
• 8 Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst. Rev. (4), CD004514 (2008).
  MedlineGoogle Scholar
• 9 Malouf R, Grimley Evans J. The effect of vitamin B6 on cognition. Cochrane Database Syst. Rev. (4), CD004393 (2003).
  MedlineGoogle Scholar
• 10 Malouf R, Areosa Sastre A. Vitamin B12 for cognition. Cochrane Database Syst Rev. (3), CD004326 (2003).
  MedlineGoogle Scholar
• 11 Ford AH, Almeida OP. Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials. J. Alzheimers Dis. 29(1), 133–149 (2012).
  Medline CASGoogle Scholar
• 12 Clarke R, Bennett D, Parish S et al. B-Vitamin Treatment Trialists’ Collaboration. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am. J. Clin. Nutr. 100(2), 657–666 (2014).
  Medline CASGoogle Scholar
• 13 Douaud G, Refsum H, de Jager CA et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl Acad. Sci. USA 110, 9523–9528 (2013).
  Medline CASGoogle Scholar
• 14 Smith AD, Smith SM, de Jager CA et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 5(9), e12244 (2010).
  MedlineGoogle Scholar
• 15 de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int. J. Geriatr. Psychiatry 27(6), 592–600 (2012).
  MedlineGoogle Scholar
• 16 Scalabrino G. The multi-faceted basis of vitamin B12 (cobalamin) neurotrophism in adult central nervous system: lessons learned from its deficiency. Prog. Neurobiol. 88(3), 203–220 (2009).
  Medline CASGoogle Scholar
• 17 Fuso A. The ‘golden age’ of DNA methylation in neurodegenerative diseases. Clin. Chem. Lab. Med. 51(3), 523–534 (2013). • This paper is a synthetic but exhaustive summary of the possible link among homocysteine, epigenetics and neurodegeneration.
  Medline CASGoogle Scholar
• 18 Seifter JL, Samuels MA. Uremic encephalopathy and other brain disorders associated with renal failure. Semin. Neurol. 31(2), 139–143 (2011).
  MedlineGoogle Scholar
• 19 Haroon NN, Austin PC, Shah BR, Wu J, Gill SS, Booth GL. Risk of dementia in seniors with newly diagnosed diabetes: a population-based study. Diabetes Care 38(10), 1868–1875 (2015).
  MedlineGoogle Scholar
• 20 de Jager J, Kooy A, Lehert P et al. Long term treatment with metformin in patients with Type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 20(340), c2181 (2010).
  Google Scholar
• 21 Kruman II, Henderson GI, Bergeson SE. DNA damage and neurotoxicity of chronic alcohol abuse. Exp. Biol. Med. (Maywood) 237(7), 740–747 (2012).
  Medline CASGoogle Scholar
• 22 O'Callaghan P, Meleady R, Fitzgerald T, Graham I, European COMAC group. Smoking and plasma homocysteine. Eur. Heart. J. 23(20), 1580–1586 (2002).
  MedlineGoogle Scholar
• 23 Mayo JN, Chen CH, Liao FF, Bearden SE. Homocysteine disrupts outgrowth of microvascular endothelium by an iNOS-dependent mechanism. Microcirculation 21(6), 541–550 (2014).
  Medline CASGoogle Scholar
• 24 Lee JT, Peng GS, Chen SY et al. Homocysteine induces cerebral endothelial cell death by activating the acid sphingomyelinase ceramide pathway. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 21–27 (2013).
  Medline CASGoogle Scholar
• 25 Zhang D, Sun X, Liu J, Xie X, Cui W, Zhu Y. Homocysteine accelerates senescence of endothelial cells via DNA hypomethylation of human telomerase reverse transcriptase. Arterioscler. Thromb. Vasc. Biol. 35(1), 71–78 (2015).
  Medline CASGoogle Scholar
• 26 Lin N, Qin S, Luo S, Cui S, Huang G, Zhang X. Homocysteine induces cytotoxicity and proliferation inhibition in neural stem cells via DNA methylation in vitro. FEBS J. 281(8), 2088–2096 (2014).
  Medline CASGoogle Scholar
• 27 Yeganeh F, Nikbakht F, Bahmanpour S, Rastegar K, Namavar R. Neuroprotective effects of NMDA and group I metabotropic glutamate receptor antagonists against neurodegeneration induced by homocysteine in rat hippocampus: in vivo study. J. Mol. Neurosci. 50(3), 551–557 (2013).
  Medline CASGoogle Scholar
• 28 Sudduth TL, Powell DK, Smith CD, Greenstein A, Wilcock DM. Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J. Cereb. Blood Flow Metab. 33(5), 708–715 (2013). • A good example of hyperhomocysteinemic animal model, of particular interest the completeness of the study design and the adoption of an exposure to moderate hyperhomocysteinemia, more relevant for interpreting human clinical outcomes (with the obvious limits of transposing laboratory animal models observation into real-life human disease).
  Medline CASGoogle Scholar
• 29 Li JG, Chu J, Barrero C, Merali S, Praticò D. Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann. Neurol. 75(6), 851–863 (2014).
  Medline CASGoogle Scholar
• 30 Zou CG, Zhao YS, Gao SY et al. Homocysteine promotes proliferation and activation of microglia. Neurobiol. Aging 31(12), 2069–2079 (2010).
  Medline CASGoogle Scholar
• 31 Ford AH, Flicker L, Alfonso H et al. Plasma homocysteine and MTHFRC677T polymorphism as risk factors for incident dementia. J. Neurol. Neurosurg. Psychiatry 83(1), 70–75 (2012).
  MedlineGoogle Scholar
• 32 Zylberstein DE, Lissner L, Bjorkelund C et al. Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol. Aging 32(3), 380–386 (2011).
  Medline CASGoogle Scholar
• 33 Hooshmand B, Solomon A, Kareholt I et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 75(16), 1408–1414 (2010).
  Medline CASGoogle Scholar
• 34 Seshadri S, Wolf PA, Beiser AS et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch. Neurol. 65(5), 642–649 (2008).
  MedlineGoogle Scholar
• 35 Bonetti F, Brombo G, Magon S, Zuliani G. Cognitive status according to homocysteine and B-group vitamins in elderly adults. J. Am. Geriatr. Soc. 63(6), 1158–1163 (2015).
  MedlineGoogle Scholar
• 36 van den Kommer TN, Dik MG, Comijs HC, Jonker C, Deeg DJ. Homocysteine and inflammation: predictors of cognitive decline in older persons? Neurobiol. Aging 31(10), 1700–1709 (2010).
  Medline CASGoogle Scholar
• 37 Ravaglia G, Forti P, Maioli F et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am. J. Clin. Nutr. 82(3), 636–643 (2005).
  Medline CASGoogle Scholar
• 38 Schafer JH, Glass TA, Bolla KI, Mintz M, Jedlicka AE, Schwartz BS. Homocysteine and cognitive function in a population-based study of older adults. J. Am. Geriatr. Soc. 53(3), 381–388 (2005).
  MedlineGoogle Scholar
• 39 Yang B, Fan S, Zhi X et al. Prevalence of hyperhomocysteinemia in China: a systematic review and meta-analysis. Nutrients 7(1), 74–90 (2014).
  MedlineGoogle Scholar
• 40 Ostrakhovitch EA, Tabibzadeh S. Homocysteine in chronic kidney disease. Adv. Clin. Chem. 72, 77–106 (2015).
  Medline CASGoogle Scholar
• 41 Lakryc EM, Machado RB, Soares JM Jr, Fernandes CE, Baracat EC. What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women? Clinics (Sao Paulo) 70(2), 107–113 (2015).
  MedlineGoogle Scholar
• 42 Testai FD, Gorelick PB. Inherited metabolic disorders and stroke part 2: homocystinuria, organic acidurias, and urea cycle disorders. Arch. Neurol. 67(2), 148–153 (2010).
  MedlineGoogle Scholar
• 43 Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J. Inherit. Metab. Dis. 34(1), 75–81 (2011).
  Medline CASGoogle Scholar
• 44 Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur. J. Med. Genet. 58(1), 1–10 (2015).
  MedlineGoogle Scholar
• 45 Liu H, Yang M, Li GM et al. The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: a meta-analysis. J. Neurol. Sci. 294(1), 74–80 (2010).
  Medline CASGoogle Scholar
• 46 Hua Y, Zhao H, Kong Y, Ye M. Association between the MTHFR gene and Alzheimer's disease: a meta-analysis. Int. J. Neurosci. 121(8), 462–471 (2011).
  Medline CASGoogle Scholar
• 47 Wu YL, Ding XX, Sun YH, Yang HY, Sun L. Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. J. Neurol. Sci. 335(1), 14–21 (2013).
  Medline CASGoogle Scholar
• 48 Weisberg IS, Jacques PF, Selhub J et al. The 1298A–>C polymorphism in methylenetetrahydrofolate reductase (MTHFR), in vitro expression and association with homocysteine. Atherosclerosis 156(2), 409–415 (2001).
  Medline CASGoogle Scholar
• 49 Leclerc D, Sibani S, Rozen R. Molecular biology of methylenetetrahydrofolate reductase (MTHFR) and overview of mutations/polymorphisms. In: Madame Curie Bioscience Database. Landes Bioscience (Ed.). Austin, TX, USA (2000). www.ncbi.nlm.nih.gov/books/NBK6561/.
  Google Scholar
• 50 Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 64(3), 169–172 (1998).
  Medline CASGoogle Scholar
• 51 Hickey SE, Curry CJ, Toriello HV. ACMG practice guideline: lack of evidence for MTHFR polymorphism testing. Genet. Med. 15(2), 153–156 (2013).
  Medline CASGoogle Scholar
• 52 Huang T, Tucker KL, Lee YC et al. Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in puerto rican adults. J. Nutr. 141(4), 654–659 (2011).
  Medline CASGoogle Scholar
• 53 Mansoori N, Tripathi M, Luthra K et al. MTHFR (677 and 1298) and IL-6-174 G/C genes in pathogenesis of Alzheimer's and vascular dementia and their epistatic interaction. Neurobiol. Aging 33(5), 1003.e1–1003.e8 (2012).
  CASGoogle Scholar
• 54 Anello G, Guéant-Rodríguez RM, Bosco P et al. Homocysteine and methylenetetrahydrofolate reductase polymorphism in Alzheimer's disease. Neuroreport 15(5), 859–861 (2004).
  Medline CASGoogle Scholar
• 55 Ueland PM. Choline and betaine in health and disease. J. Inherit. Metab. Dis. 34(1), 3–15 (2011).
  Medline CASGoogle Scholar
• 56 Gunduz M, Gunduz E, Kircelli F, Okur N, Ozkaya M. Role of surrogate markers of atherosclerosis in clinical and subclinical thyroidism. Int. J. Endocrinol. 2012, 109797 (2012).
  MedlineGoogle Scholar
• 57 van Guldener C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol. Dial. Transplant. 21(5), 1161–1166 (2006).
  MedlineGoogle Scholar
• 58 Kang A, Nigwekar SU, Perkovic V et al. Interventions for lowering plasma homocysteine levels in kidney transplant recipients. Cochrane Database Syst. Rev. 5, CD007910 (2015).
  Google Scholar
• 59 Huang T, Ren J, Huang J, Li D. Association of homocysteine with Type 2 diabetes: a meta-analysis implementing Mendelian randomization approach. BMC Genomics 14, 867 (2013).
  MedlineGoogle Scholar
• 60 Wijekoon EP, Brosnan ME, Brosnan JT. Homocysteine metabolism in diabetes. Biochem. Soc. Trans. 35(Pt 5), 1175–1179 (2007).
  Medline CASGoogle Scholar
• 61 Kwak HC, Kim YM, Oh SJ, Kim SK. Sulfur amino acid metabolism in Zucker diabetic fatty rats. Biochem. Pharmacol. 96(3), 256–266 (2015).
  Medline CASGoogle Scholar
• 62 Das M, Ghose M, Borah NC, Choudhury N. A community based study of the relationship between homocysteine and some of the life style factors. Indian J. Clin. Biochem. 25(3), 295–301 (2010).
  Medline CASGoogle Scholar
• 63 Chrysohoou C, Panagiotakos DB, Pitsavos C et al. The associations between smoking, physical activity, dietary habits and plasma homocysteine levels in cardiovascular disease-free people: the ‘ATTICA’ study. Vasc. Med. 9(2), 117–123 (2004).
  MedlineGoogle Scholar
• 64 Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 62(4), 605–616 (2002).
  Medline CASGoogle Scholar
• 65 Zoccolella S, Martino D, Defazio G, Lamberti P, Livrea P. Hyperhomocysteinemia in movement disorders: current evidence and hypotheses. Curr. Vasc. Pharmacol. 4(3), 237–243 (2006).
  Medline CASGoogle Scholar
• 66 Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P. Elevated homocysteine levels in Parkinson's disease: is there anything besides L-dopa treatment? Curr. Med. Chem. 17(3), 213–221 (2010).
  Medline CASGoogle Scholar
• 67 Miller JW. Homocysteine, folate deficiency, and Parkinson's disease. Nutr. Rev. 60(12), 410–413 (2002).
  MedlineGoogle Scholar
• 68 Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 80(1), 101–110 (2002).
  Medline CASGoogle Scholar
• 69 Zoccolella S, Lamberti SV, Iliceto G, Santamato A, Lamberti P, Logroscino G. Hyperhomocysteinemia in L-dopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia? Curr. Med. Chem. 17(28), 3253–3261 (2010).
  Medline CASGoogle Scholar
• 70 Sharma M, Tiwari M, Tiwari RK. Hyperhomocysteinemia: impact on neurodegenerative diseases. Basic Clin. Pharmacol. Toxicol. 117(5), 287–296 (2015).
  Medline CASGoogle Scholar
• 71 Ientile R, Curro’ M, Ferlazzo N, Condello S, Caccamo D, Pisani F. Homocysteine, vitamin determinants and neurological diseases. Front. Biosci. (Schol. Ed.) 2, 359–372 (2010).
  MedlineGoogle Scholar
• 72 Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69(24), 2197–2204 (2007). • Describes a fact of paramount importance in discussing about neurodegeneration, basic for clinical transposition of single-etiology mechanisms: in most cases cognitive impairment and dementia are a phenotypic manifestation of multiple causes, especially in later life. It is essential to contextualize the effect of a neurotoxic/neurodegenerative process in the global pathological burden of the patient.
  MedlineGoogle Scholar
• 73 Genoud V, Lauricella AM, Kordich LC, Quintana I. Impact of homocysteine-thiolactone on plasma fibrin networks. J. Thromb. Thrombolysis 38(4), 540–545 (2014).
  Medline CASGoogle Scholar
• 74 Jakubowski H. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv. Exp. Med. Biol. 660, 113–127 (2010).
  Medline CASGoogle Scholar
• 75 Sharma GS, Kumar T, Dar TA, Singh LR. Protein N-homocysteinylation: from cellular toxicity to neurodegeneration. Biochim. Biophys. Acta 1850(11), 2239–2245 (2015).
  Medline CASGoogle Scholar
• 76 McCully KS. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann. Clin. Lab. Sci. 39(3), 219–232 (2009). • A complete review. It exposes relevant evidences, an original point of view and courageous hypothesis.
  Medline CASGoogle Scholar
• 77 McCully KS. Chemical pathology of homocysteine. V. Thioretinamide, thioretinaco, and cystathionine synthase function in degenerative diseases. Ann. Clin. Lab. Sci. 41(4), 301–314 (2011).
  Medline CASGoogle Scholar
• 78 Boldyrev A, Bryushkova E, Mashkina A, Vladychenskaya E. Why is homocysteine toxic for the nervous and immune systems? Curr. Aging Sci. 6(1), 29–36 (2013).
  Medline CASGoogle Scholar
• 79 Boldyrev AA. Molecular mechanisms of homocysteine toxicity. Biochemistry (Mosc) 74(6), 589–598 (2009).
  Medline CASGoogle Scholar
• 80 McCully KS. The active site of oxidative phosphorylation and the origin of hyperhomocysteinemia in aging and dementia. Ann. Clin. Lab. Sci. 45(2), 222–225 (2015).
  Medline CASGoogle Scholar
• 81 Abushik PA, Niittykoski M, Giniatullina R et al. The role of NMDA and mGluR5 receptors in calcium mobilization and neurotoxicity of homocysteine in trigeminal and cortical neurons and glial cells. J. Neurochem. 129(2), 264–274 (2014).
  Medline CASGoogle Scholar
• 82 McBean GJ. The transsulfuration pathway: a source of cysteine for glutathione in astrocytes. Amino Acids 42(1), 199–205 (2012).
  Medline CASGoogle Scholar
• 83 Chen NC, Yang F, Capecci LM et al. Regulation of homocysteine metabolism and methylation in human and mouse tissues. FASEB J. 24(8), 2804–2817 (2010).
  Medline CASGoogle Scholar
• 84 Stefaniak J, O'Brien J. Imaging of neuroinflammation in dementia: a review. J. Neurol. Neurosurg. Psychiatry 87(1), 21–28 (2016).
  MedlineGoogle Scholar
• 85 Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl. Neurodegener. 12, 4–19 (2015).
  Google Scholar
• 86 Surendranathan A, Rowe JB, O'Brien JT. Neuroinflammation in Lewy body dementia. Parkinsonism Relat. Disord. 21(12), 1398–1406 (2015).
  MedlineGoogle Scholar
• 87 Azizi G, Mirshafiey A. The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis. Immunopharmacol. Immunotoxicol. 34(6), 881–895 (2012).
  Medline CASGoogle Scholar
• 88 Scherer EB, Loureiro SO, Vuaden FC et al. Mild hyperhomocysteinemia increases brain acetylcholinesterase and proinflammatory cytokine levels in different tissues. Mol. Neurobiol. 50(2), 589–596 (2014).
  Medline CASGoogle Scholar
• 89 da Cunha AA, Ferreira AG, Loureiro SO et al. Chronic hyperhomocysteinemia increases inflammatory markers in hippocampus and serum of rats. Neurochem. Res. 37(8), 1660–1669 (2012).
  Medline CASGoogle Scholar
• 90 McCully KS. Homocysteine and the pathogenesis of atherosclerosis. Expert Rev. Clin. Pharmacol. 8(2), 211–219 (2015).
  Medline CASGoogle Scholar
• 91 Scherer EB, Loureiro SO, Vuaden FC et al. Mild hyperhomocysteinemia increases brain acetylcholinesterase and proinflammatory cytokine levels in different tissues. Mol. Neurobiol. 50(2), 589–596 (2014).
  Medline CASGoogle Scholar
• 92 da Cunha AA, Ferreira AG, Loureiro SO et al. Chronic hyperhomocysteinemia increases inflammatory markers in hippocampus and serum of rats. Neurochem. Res. 37(8), 1660–1669 (2012).
  Medline CASGoogle Scholar
• 93 Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain Behav. Immun. 19(6), 493–499 (2005).
  Medline CASGoogle Scholar
• 94 Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J. Intern. Med. 265(6), 663–679 (2009).
  Medline CASGoogle Scholar
• 95 Guest J, Bilgin A, Hokin B, Mori TA, Croft KD, Grant R. Novel relationships between B12, folate and markers of inflammation, oxidative stress and NAD(H) levels, systemically and in the CNS of a healthy human cohort. Nutr. Neurosci. (8), 355–364 (2015).
  MedlineGoogle Scholar
• 96 Eren E, Ellidag HY, Aydin O, Yılmaz N. Homocysteine, paraoxonase-1 and vascular endothelial dysfunction: omnibus viis romam pervenitur. J. Clin. Diagn. Res. 8(9), CE01–CE04 (2014).
  MedlineGoogle Scholar
• 97 Wang XC, Sun WT, Yu CM et al. ER stress mediates homocysteine-induced endothelial dysfunction: modulation of IKCa and SKCa channels. Atherosclerosis 242(1), 191–198 (2015).
  Medline CASGoogle Scholar
• 98 Ravnskov U, McCully KS. Review and hypothesis: vulnerable plaque formation from obstruction of Vasa vasorum by homocysteinylated and oxidized lipoprotein aggregates complexed with microbial remnants and LDL autoantibodies. Ann. Clin. Lab. Sci. 39(1), 3–16 (2009).
  Medline CASGoogle Scholar
• 99 Vermeer SE, van Dijk EJ, Koudstaal PJ et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam scan study. Ann. Neurol. 51(3), 285–289 (2002).
  Medline CASGoogle Scholar
• 100 Tangney CC, Aggarwal NT, Li H et al. Vitamin B12, cognition, and brain MRI measures: a cross-sectional examination. Neurology 77(13), 1276–1282 (2011).
  Medline CASGoogle Scholar
• 101 Kamat PK, Vacek JC, Kalani A, Tyagi N. Homocysteine induced cerebrovascular dysfunction: a link to Alzheimer's disease etiology. Open. Neurol. J. 9, 9–14 (2015).
  Medline CASGoogle Scholar
• 102 Fuso A, Nicolia V, Cavallaro RA, Scarpa S. DNA methylase and demethylase activities are modulated by one-carbon metabolism in Alzheimer's disease models. J. Nutr. Biochem. 22(3), 242–251 (2011). • Pioneering article on a possible concrete link between hyperhomocysteinemia and Alzheimer's disease.
  Medline CASGoogle Scholar
• 103 Ji C, Kaplowitz N. Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury. World J. Gastroenterol. 10(12), 1699–1708 (2004).
  Medline CASGoogle Scholar
• 104 Althausen S, Paschen W. Homocysteine-induced changes in mRNA levels of genes coding for cytoplasmic- and endoplasmic reticulum-resident stress proteins in neuronal cell cultures. Brain Res. Mol. Brain Res. 84(1), 32–40 (2000).
  Medline CASGoogle Scholar
• 105 Kim HJ, Cho HK, Kwon YH. Synergistic induction of ER stress by homocysteine and beta-amyloid in SH-SY5Y cells. J. Nutr. Biochem. 19(11), 754–761 (2008).
  Medline CASGoogle Scholar
• 106 Slodzinski H, Moran LB, Michael GJ et al. Homocysteine-induced endoplasmic reticulum protein (herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies. Clin. Neuropathol. 28(5), 333–343 (2009).
  Medline CASGoogle Scholar
• 107 Doyle KM, Kennedy D, Gorman AM, Gupta S, Healy SJ, Samali A. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J. Cell. Mol. Med. 15(10), 2025–2039 (2011).
  Medline CASGoogle Scholar
• 108 Nurk E, Tell GS, Vollset SE et al. Changes in lifestyle and plasma total homocysteine: the Hordaland Homocysteine Study. Am. J. Clin. Nutr. 79(5), 812–819 (2004).
  Medline CASGoogle Scholar
• 109 Stabler SP. Clinical practice. Vitamin B12 deficiency. N. Engl. J. Med. 368(2), 149–160 (2013).
  Medline CASGoogle Scholar
• 110 Zeman M, Zák A, Vecka M, Tvrzická E, Písaríková A, Stanková B. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J. Nutr. Biochem. 17(6), 379–384 (2006).
  Medline CASGoogle Scholar
• 111 Zinellu A, Sotgia S, Pisanu E et al. LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. Eur. J. Pharm. Sci. 47(1), 117–123 (2012).
  Medline CASGoogle Scholar
• 112 Drewes YM, Poortvliet RK, Blom JW et al. Homocysteine levels and treatment effect in the PROspective study of pravastatin in the elderly at Risk. J. Am. Geriatr. Soc. 62(2), 213–221 (2014).
  MedlineGoogle Scholar
• 113 Santilli F, Davì G, Patrono C. Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: a mechanistic and clinical perspective. Vascul. Pharmacol. 78, 1–9 (2015).
  MedlineGoogle Scholar
• 114 Veeranna V, Zalawadiya SK, Niraj A et al. Homocysteine and reclassification of cardiovascular disease risk. J. Am. Coll. Cardiol. 58(10), 1025–1033 (2011).
  Medline CASGoogle Scholar
• 115 Hankey GJ, Eikelboom JW, Yi Q et al. VITATOPS trial study group. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol. 11(6), 512–520 (2012).
  Medline CASGoogle Scholar
• 116 Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog. Lipid. Res. 60, 50–73 (2015).
  Medline CASGoogle Scholar
• 117 Borowczyk K, Shih DM, Jakubowski H. Metabolism and neurotoxicity of homocysteine thiolactone in mice: evidence for a protective role of paraoxonase 1. J. Alzheimers Dis. 30(2), 225–231 (2012).
  Medline CASGoogle Scholar
• 118 Perla-Kaján J, Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J. 24(3), 931–936 (2010).
  Medline CASGoogle Scholar
• 119 Ataie A, Sabetkasaei M, Haghparast A, Moghaddam AH, Kazeminejad B. Neuroprotective effects of the polyphenolic antioxidant agent, Curcumin, against homocysteine-induced cognitive impairment and oxidative stress in the rat. Pharmacol. Biochem. Behav. 96(4), 378–385 (2010).
  Medline CASGoogle Scholar
• 120 Machado FR, Ferreira AG, da Cunha AA et al. Homocysteine alters glutamate uptake and Na⁺, K⁺-ATPase activity and oxidative status in rats hippocampus: protection by vitamin C. Metab. Brain Dis. 26(1), 61–67 (2011).
  Medline CASGoogle Scholar
• 121 Hildebrandt W, Sauer R, Bonaterra G, Dugi KA, Edler L, Kinscherf R. Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status. Am. J. Clin. Nutr. 102(5), 1014–1024 (2015).
  Medline CASGoogle Scholar
• 122 Kamat PK, Kalani A, Tyagi SC, Tyagi N. Hydrogen sulfide epigenetically attenuates homocysteine-induced mitochondrial toxicity mediated through NMDA receptor in mouse brain endothelial (bEnd3) cells. J. Cell. Physiol. 230(2), 378–394 (2015).
  Medline CASGoogle Scholar
• 123 Kamat PK, Kalani A, Givvimani S, Sathnur PB, Tyagi SC, Tyagi N. Hydrogen sulfide attenuates neurodegeneration and neurovascular dysfunction induced by intracerebral-administered homocysteine in mice. Neuroscience 252, 302–319 (2013).
  Medline CASGoogle Scholar
• 124 Fuso A, Nicolia V, Ricceri L et al. S-adenosylmethionine reduces the progress of the Alzheimer-like features induced by B-vitamin deficiency in mice. Neurobiol. Aging 33(7), 1482.e1–1482.e16 (2012).
  Medline CASGoogle Scholar
• 125 Halliday M, Mallucci GR. Targeting the unfolded protein response in neurodegeneration: a new approach to therapy. Neuropharmacology 76(Pt A), 169–174 (2014).
  Medline CASGoogle Scholar